^
Association details:
| Biomarker: | MSI-H/dMMR + MLH1 deletion + PMS2 deletion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Mismatch Repair (MMR) gene alteration and BRAF V600E mutation are potential predictive biomarkers of immune checkpoint inhibitors in MMR-deficient colorectal cancer
Published date:
02/25/2021
Excerpt:
A total of 60 CRC patients with MMR-D/MSI-H who previously received ICI were identified…Patients with MLH1/ PMS2 loss had worse 1-year and 2-year PFS rates compared to patients with MSH2/MSH6 loss (84.2% vs 57.8% and 78.2% vs 54.2%, respectively; p<0.001)....BRAF V600E mutation, MLH1 and/or PMS2 loss, as well as age >65 years and liver metastasis may be predictive of duration of ICI response in MMR-deficient CRC patients.
DOI:
10.1002/onco.13741
